These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 18452533)

  • 1. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens.
    Saha S; Savage PB; Bal M
    J Appl Microbiol; 2008 Sep; 105(3):822-8. PubMed ID: 18452533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria.
    Isogai E; Isogai H; Takahashi K; Okumura K; Savage PB
    Oral Microbiol Immunol; 2009 Apr; 24(2):170-2. PubMed ID: 19239645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
    Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
    J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
    Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.
    Paterson DL
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S14-20. PubMed ID: 18713045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli.
    Donskey CJ
    Clin Infect Dis; 2006 Sep; 43 Suppl 2():S62-9. PubMed ID: 16894517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of antibiotic resistance characteristics of Gram-negative bacteria isolated from laying hens and eggs in conventional and organic keeping systems in Bavaria, Germany.
    Schwaiger K; Schmied EM; Bauer J
    Zoonoses Public Health; 2008 Sep; 55(7):331-41. PubMed ID: 18667026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant Gram-negative bacteria in postoperative infections.
    Singh AV; Mishra B; Thakur A
    J Indian Med Assoc; 2009 Mar; 107(3):148-50, 163. PubMed ID: 19810380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampicin combined regimens for gram-negative infections: data from the literature.
    Drapeau CM; Grilli E; Petrosillo N
    Int J Antimicrob Agents; 2010 Jan; 35(1):39-44. PubMed ID: 19815392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic challenge of Gram-negative sepsis: prolonging the lifespan of a scarce resource.
    Richards GA
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():18-22. PubMed ID: 16209702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan.
    Saghir S; Faiz M; Saleem M; Younus A; Aziz H
    Indian J Med Microbiol; 2009; 27(4):341-7. PubMed ID: 19736404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting back: peptidomimetics as a new weapon in the battle against antibiotic resistance.
    Bragonzi A
    Sci Transl Med; 2010 Mar; 2(21):21ps9. PubMed ID: 20374995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopeptide Antibiotic To Overcome the Intrinsic Resistance of Gram-Negative Bacteria.
    Yarlagadda V; Manjunath GB; Sarkar P; Akkapeddi P; Paramanandham K; Shome BR; Ravikumar R; Haldar J
    ACS Infect Dis; 2016 Feb; 2(2):132-9. PubMed ID: 27624964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.
    Lomovskaya O; Bostian KA
    Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.